A fast, early and widespread flu season has gripped the United States, though deaths and hospitalizations are still below pandemic thresholds.
Emergent BioSolutions snagged the exclusive right to manufacture and sell VaxInnate's flu vaccine, a product Emergent can produce quickly at high yields and low cost.
Roche has spent the past few months getting raked over the coals by critics who say the company has not offered full and complete access to Tamiflu data. So when the FDA extended the approval of the flu drug, the news came as a much-needed boost.
A universal influenza vaccine is the virtual Holy Grail for flu scientists, and a researcher and his collaborators at Georgia State University's Center for Inflammation, Immunity and Infection moved a step closer to developing the elusive shot.
The FDA gave the OK to GlaxoSmithKline's new four-strain seasonal flu vaccine, which the company said will become available for the 2013-2014 flu season.
An early flu season is under way, the national Centers for Disease Control and Prevention reports, and will likely prove formidable.
When it comes to flu pandemics, making and distributing vaccines quickly is of utmost importance. And now German scientists have developed an RNA vaccine that could cut flu vaccine production time from months to weeks.
What do less-than-stellar vaccination rates mean for sales? Looking at actual worldwide 2011 sales numbers and estimated worldwide 2012 sales numbers provided by EvaluatePharma, it seems sales as a whole are only slightly up for the top 10 best-selling flu vaccines. Read more >>
Italy lifted a ban on Novartis' flu vaccine several weeks after halting distribution due to small virus particles found in some injections.
Gates Foundation backs $13M venture add for flu drug developer
The Bill & Melinda Gates Foundation has stepped up with another equity investment in a biotech company, this time making a major contribution to a $13 million Series A add for a startup aiming at a universal preventive as well as therapeutic approach to influenza. Omega Funds also joined the venture top-up, bringing the first venture round for Cambridge, MA-based Visterra to $26 million.